Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aegon Ltd. (AEG) vs Smith & Nephew plc (SNN) Price & Performance

Aegon Ltd.Trade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Aegon Ltd. vs Smith & Nephew plc — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.01B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Aegon Ltd. and Smith & Nephew plc are close in size by market cap, and Aegon Ltd. pays the higher dividend (4.94%). Which is the better fit depends on your goals.

AEGSNN
Market Cap
$14.01B$12.54B
Sector
FinancialsHealth
52-Week High
$9.53$38.70
52-Week Low
$6.79$28.73
Enterprise Value
$15.16B$15.57B
Dividend Yield
4.94%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aegon Ltd.

AEG trades at $9.415, down 0.37% on the day, with a bullish technical signal from moving averages. The company reported mixed recent earnings, beating expectations in Q2 and Q3 2025 but missing in Q4. Revenue for 2024 was $19.52 billion, with net income of $688 million. A dividend of $0.25 per share is scheduled for payment in July 2026. The balance sheet shows total assets of $327.39 billion and a declining debt-to-asset ratio, improving from 2.43 in 2020 to 1.46 in 2024.

AEG presents a moderate investment case with a low P/E of 13.54 and P/S of 0.57, suggesting potential undervaluation. Analyst sentiment is mixed with a 27.78% buy rating. Key risks include volatile cash flows and execution of strategic shifts, such as the relocation to the U.S. and partnership developments. The stock's outlook hinges on sustained profitability and successful implementation of corporate simplifications.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About Aegon Ltd.

Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.

Read more on AEG

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN